Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles

Business Wire, Nov 3, 2006

NEW YORK -- Rodman & Renshaw Healthcare Conference 2006 takes place 6-8 November at the New York Palace Hotel in New York. For in-depth information about the conference, visit http://www.rodmanandrenshaw.com/us06conference.

Below are profiles from Rodman & Renshaw Healthcare Conference 2006 exhibitors. Business Wire is the official news wire service for Rodman & Renshaw Healthcare Conference. Breaking news is available at http://www.tradeshownews.com, Business Wire's trade show, conference and event news resource.

Company: Ablynx nv

Investor Relations Contact: Dr. Edwin Moses, Chairman & CEO

Phone: +32-9-261-06-32

E-mail: edwin.moses@ablynx.com

Web: http://www.ablynx.com

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies[R], a novel class of antibody-derived therapeutic proteins, for a range of human diseases.

Ablynx's most advanced Nanobody[R] programs in acute thrombosis and inflammation show tremendous therapeutic potential in vivo and are approaching human clinical testing. The Company expects to initiate its first clinical trial in early 2007.

The company began operations in 2002 in Ghent, Belgium and currently employs ~80 staff.

Nanobodies[R] are unique and highly versatile single domain antibodies. Because of their small size, unique structure and unparalleled stability, Nanobodies[R] combine the beneficial features of conventional antibodies (such as affinity and selectivity) with the desirable properties of small molecules.

Company: Acceleron Pharma

Media Contact: Paul Kidwell, Kidwell PR, 617-296-3854

Investor Relations Contact: Steven Ertel, 617-576-2220, x234

Phone: 617-576-2220

Web: www.acceleronpharma.com

Acceleron Pharma, Inc. is a biopharmaceutical company developing regenerative therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases. Acceleron was founded to take advantage of its unique insight on the Growth and Differentiation Factor (GDF) protein family. Acceleron is utilizing a novel approach to modulate the activity of various GDFs that control tissue growth thereby unleashing the body's inherent ability to rebuild and re-grow damaged or lost tissue. Acceleron is establishing itself as the premier company in the field of regenerative biotherapeutics with its lead program, ACE-011, is phase 1 trials for the treatment of bone loss

Company: Access Pharmaceuticals, Inc.

Ticker Symbol & Exchange: ACCP.OB

Media Contact: Rosemay Mazanet, Acting CEO

Investor Relations Contact: Donald C. Weinberger

Phone: 212-370-4500

E-mail: rosemary.mazanet@accesspharma.com

Web: www.accesspharma.com

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac[TM], currently in Phase II clinical testing of patients with ovarian cancer, and MuGard[TM], for the treatment of patients with mucositis.

The Company also has other advanced drug delivery technologies, including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

Company: Acorda Therapeutics

Ticker Symbol & Exchange: ACOR

Investor Relations Contact: Erica Wishner

Phone: 914-347-4300 ext. 162

E-mail: ewishner@acorda.com

Web: www.acorda.com

Acorda Therapeutics[R] is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Acorda's marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride) and Zanaflex[R] (tizanidine hydrochloride) tablets. The Company announced positive results from its Phase 3 clinical trial of Fampridine-SR, the Company's lead product candidate, for the improvement of walking ability in people with MS in September 2006. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.

Company: Active Biotech AB

Ticker Symbol & Exchange: ACTI.ST (SEK)

Investor Relations Contact: Cecilia Hofvander

Phone: +46-46-19-20-00

E-mail: Cecilia.hofvander@activebiotech.com

Web: www.activebiotech.com

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex[R] for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.